12:00 AM
 | 
Jul 24, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Maxamine histamine dihydrochloride regulatory update

MAXM submitted an NDA to the FDA for its Maxamine histamine dihydrochloride as an adjuvant to...

Read the full 59 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >